BTIG Maintains Buy on Viridian Therapeutics, Raises Price Target to $61
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Julian Harrison maintains a Buy rating on Viridian Therapeutics and raises the price target from $56 to $61.
September 26, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Julian Harrison has reaffirmed a Buy rating for Viridian Therapeutics and increased the price target from $56 to $61, indicating confidence in the company's future performance.
The increase in the price target from $56 to $61 by BTIG suggests a positive outlook on Viridian Therapeutics' future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100